Arbutus Biopharma Corporation (ABUS) financial statements (2021 and earlier)

Company profile

Business Address 100-8900 GLENLYON PARKWAY
BURNABY, BC V5J 5J8
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:123911251261311810
Cash and cash equivalents523237542316772
Short-term investments715988721071540
Other undisclosed cash, cash equivalents, and short-term investments0     (112)
Receivables1121113
Other undisclosed current assets323211114
Total current assets:12894129129133184116
Noncurrent Assets
Operating lease, right-of-use asset2 
Property, plant and equipment791012732
Long-term investments and receivables  22  10 
Long-term investments  22  10 
Intangible assets, net (including goodwill)  6683124515 
Goodwill  222424163 
Intangible assets, net (excluding goodwill)  445999353 
Restricted cash and investments   1313  
Other noncurrent assets00     
Other undisclosed noncurrent assets 3     
Total noncurrent assets:912991081435282
TOTAL ASSETS:137106228237276712118
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:979111099
Accounts payable323233 
Accrued liabilities111112 
Other undisclosed accounts payable and accrued liabilities5458559
Restructuring reserve 01    
Deferred revenue and credits3016
Other undisclosed current liabilities1101115
Total current liabilities:1081115111120
Noncurrent Liabilities
Long-term debt and lease obligation3  1212  
Long-term debt, excluding current maturities   1212  
Operating lease, liability3 
Liabilities, other than long-term debt334285015410
Deferred revenue and credits1 010
Deferred rent credit  1
Deferred tax liabilities, net 1741146 
Business combination, contingent consideration, liability3331097 
Other undisclosed noncurrent liabilities202213    
Total noncurrent liabilities:262516406215410
Total liabilities:353328557316530
Stockholders' equity
Stockholders' equity attributable to parent, including:1027320018220354888
Preferred stock   49   
Common stock986899879876867834290
Additional paid in capital61554843373026
Accumulated other comprehensive loss(48)(48)(48)(48)(50)(50)(22)
Accumulated deficit(1,046)(970)(805)(738)(651)(267)(206)
Warrants and rights outstanding      5
Other undisclosed stockholders' equity attributable to parent1491371261  (5)
Total stockholders' equity:1027320018220354888
TOTAL LIABILITIES AND EQUITY:137106228237276712118

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net1112515
Gross profit:7661112515
Operating expenses(65)(150)(96)(122)(493)(127)(48)
Operating loss:(58)(144)(90)(111)(492)(102)(33)
Nonoperating income (expense)(6)(22)2822255
Investment income, nonoperating12282111
Foreign currency transaction gain (loss), before tax(0)0(1)21224
Interest and debt expense(4)(2)(0)(0)   
Other undisclosed income from continuing operations before equity method investments, income taxes  00   
Loss from continuing operations before equity method investments, income taxes:(68)(168)(61)(109)(489)(77)(28)
Other undisclosed income from continuing operations before income taxes42     
Loss from continuing operations before income taxes:(64)(166)(61)(109)(489)(77)(28)
Income tax benefit 1342410516 
Net loss:(64)(154)(57)(84)(384)(61)(28)
Other undisclosed net loss attributable to parent      (11)
Net loss attributable to parent:(64)(154)(57)(84)(384)(61)(39)
Preferred stock dividends and other adjustments(12)(11)(10)(1)   
Net loss available to common stockholders, diluted:(76)(165)(67)(85)(384)(61)(39)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(64)(154)(57)(84)(384)(61)(28)
Other comprehensive income (loss)0(0)0    
Comprehensive loss:(64)(154)(57)(84)(384)(61)(28)
Comprehensive income, net of tax, attributable to noncontrolling interest0      
Other undisclosed comprehensive loss, net of tax, attributable to parent     (27)(17)
Comprehensive loss, net of tax, attributable to parent:(64)(154)(57)(84)(384)(89)(45)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: